Nurix Therapeutics (NRIX) Return on Capital Employed (2020 - 2026)
Nurix Therapeutics' (NRIX) quarterly Return on Capital Employed came in at 70.29% in Q2 2026, down 2662.0% year-on-year from 2.74% in Q2 2025, and down 27.06% on a QoQ basis from 55.32% in Q1 2026.
Nurix Therapeutics (NRIX) Return on Capital Employed (2020 - 2026) Analysis & Trends
Nurix Therapeutics (NRIX) has 7 years of Return on Capital Employed data on file, last reported at 70.29% in Q2 2026.
- On a quarterly basis, Return on Capital Employed fell 2662.0% year-over-year to 70.29% in Q2 2026; TTM through May 2026 was 70.29%, a 2662.0% decrease from a year earlier, with the FY2025 full-year figure at 48.23%, up 290.0% from the prior year.
- Return on Capital Employed for Q2 2026 stood at 70.29%, down from 55.32% in the prior quarter.
- Over the last five years, Return on Capital Employed for NRIX reached as high as 34.79% in Q1 2022 and fell as low as 70.29% in Q2 2026.
- Historically, Return on Capital Employed has averaged 52.38% across 5 years, with a median of 54.58% in 2024.
- Across the five-year window, Return on Capital Employed jumped 2205 bps in 2025 and plunged 2662 bps in 2026, its largest moves.
- Year by year, Return on Capital Employed stood at 50.05% in 2022, then slipped by 26 bps to 63.31% in 2023, then soared by 32 bps to 42.98% in 2024, then fell by 28 bps to 55.06% in 2025, then declined by 28 bps to 70.29% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 70.29% in Q2 2026, 55.32% in Q1 2026, and 55.06% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Nurix Therapeutics | 2.64 Bn | 2.19 Bn | - | -70.29% |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | -70.29% |
| Feb 28, 2026 | -55.32% |
| Nov 30, 2025 | -55.06% |
| Aug 31, 2025 | -56.30% |
| May 31, 2025 | -43.67% |
| Feb 28, 2025 | -41.77% |
| Nov 30, 2024 | -42.98% |
| Aug 31, 2024 | -45.47% |
| May 31, 2024 | -54.10% |
| Feb 29, 2024 | -63.82% |
| Nov 30, 2023 | -63.31% |
| Aug 31, 2023 | -59.13% |
| May 31, 2023 | -57.31% |
| Feb 28, 2023 | -56.02% |
| Nov 30, 2022 | -50.05% |
| Aug 31, 2022 | -48.18% |
| May 31, 2022 | -45.26% |
| Feb 28, 2022 | -34.79% |
| Nov 30, 2021 | -28.16% |
| Aug 31, 2021 | -21.97% |